EZH2 and cancer: ZLD1039 inhibited breast cancer metastasis in the present study likely by the suppression of CDH1. Therefore, the combined effects of ZLD1039-mediated EZH2 inhibition on several cancer pathways likely mediates the dramatic antitumor activity seen in the breast cancer models.